A Snapshot seminar hosted by the School of Physiology, Pharmacology and Neuroscience
M1 muscarinic acetylcholine receptors are an established therapeutic target for improving cognitive decline in Alzheimer’s disease (AD). Attempts to target the M1-receptor clinically produced beneficial cognitive effects in AD and schizophrenia, but were hampered by cholinergic side effects. Our recent data shows that in addition to pro-cognitive benefits, M1-receptor ligands can display disease-modifying effects in preclinical models of neurodegenerative disease. Furthermore, we have developed a toolbox of chemogenetic and biased M1-receptor mutant mouse models to (i) fully understand the physiological role and therapeutic value of selective M1-receptor activation, and (ii) to define the pharmacological principles required in an M1-receptor ligand in order to mediate clinically beneficial effects and avoid adverse responses.
Join via Zoom: https://bristol-ac-uk.zoom.us/j/4798119105?pwd=MlZRZEt6aWhQb0NYT2pXd3N5aVRvQT09
Host: Eamonn Kelly
Dr Sophie Bradley (https://www.gla.ac.uk/researchinstitutes/biology/staff/sophiebradley/)